Cognitive test results in pediatric MS
What do racial disparities tell us?
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Heterogeneity in physical and cognitive outcomes is a well-recognized but little understood feature of multiple sclerosis (MS). Such heterogeneity likely reflects the contribution of multiple factors including genetics, physical environment, social environment, comorbid diseases, and health behaviors. Increasingly, race and ethnicity are being studied as possible factors influencing MS-related outcomes.1
In this issue of Neurology®, Ross et al.2 examined 42 patients with pediatric-onset MS to determine whether race is associated with differences in cognition. Each study participant underwent testing to evaluate global functioning, complex attention, verbal fluency, confrontation naming, and verbal memory. The 20 African American (AA) subjects did not perform as well as the 22 Caucasian American (CA) subjects on tests of complex attention and language. Previous studies of the pediatric MS population showed a high burden of cognitive impairment and difficulties with complex attention and language; the burden of impairment increased with longer disease duration, earlier age at onset, increasing number of relapses, and level of physical disability.3,4 Ross et al. extend earlier findings by focusing on a patient-related characteristic, race, on cognitive impairment rather than on disease-related characteristics such as age …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Contemporary Issues in Practice, Education, & Research
Factors Associated With, and Mitigation Strategies for, Health Care Disparities Faced by Patients With Headache DisordersJessica Kiarashi, Juliana VanderPluym, Christina L. Szperka et al.Neurology, June 09, 2021 -
Research Article
Association of Disease Severity and Socioeconomic Status in Black and White Americans With Multiple SclerosisKarla Gray-Roncal, Kathryn C. Fitzgerald, Lana Zhovtis Ryerson et al.Neurology, June 30, 2021 -
Articles
Rapid disease course in African Americans with multiple sclerosisI. Kister, E. Chamot, J.H. Bacon et al.Neurology, July 19, 2010 -
Clinical and Ethical Challenges
Multiple sclerosis in US minority populationsClinical practice insightsOmar Khan, Mitzi J. Williams, Lilyana Amezcua et al.Neurology: Clinical Practice, January 16, 2015